More than 8,000 Xarelto lawsuits currently await trial. Similar lawsuits against blood thinner Pradaxa resulted in a $650 million settlement.
Xarelto, the blood thinner manufactured by Bayer and marketed by Janssen Pharmaceuticals (subsidiary of Johnson & Johnson), has been linked to thousands of adverse events and fatalities among patients. The medication was approved by the FDA in 2011 as a superior alternative to anticoagulants like warfarin, and has since been prescribed to more than 23 million patients worldwide. However, Xarelto is linked to a high risk of excessive bleeding, without an antidote to stop it.
Thousands of personal injury and wrongful death lawsuits await trial in a multidistrict litigation and mass tort against Bayer and Janssen Pharmaceuticals. Similar pharmaceutical litigation suggests that these lawsuits could result in millions of dollars in compensation.
Xarelto Multidistrict Litigation (MDL)—Louisiana (Pending)
More than 7,000 Xarelto personal injury and wrongful death lawsuits await trial in a pending MDL in Louisiana federal court. Bellwether cases will begin trial February 2017.
The complaints allege that Janssen Pharmaceuticals failed to warn clients about the severe side effects of taking Xarelto, including excessive bleeding which the drug has no antidote for.
Xarelto Mass Tort—Philadelphia (Pending)
A Philadelphia mass tort program includes nearly 1,000 cases awaiting trial. Similar to the Louisiana MDL, lawsuits accuse Janssen Pharmaceuticals of failure to warn and putting patients at risk of uncontrollable bleeding.
Bellwether cases are scheduled to begin August 2017.
$2.37 Billion Actos Settlement (2015)
Actos, a type-2 diabetes medication, put patients at increased risk of developing bladder cancer. In 2015, manufacturer Takeda Pharmaceutical Co. settled 8,000 cases for negligence. Lawsuits accused the company of failing to warn patients of the link between Actos and an increased risk of bladder cancer, despite prior knowledge of this connection.
Under the $2.37 billion settlement, claimants received an average of $296,000 in compensation.
$56.9 Million Bayer Corporation Settlement (2015)
In 2015, Bayer ended litigation for their Yaz, Yasmin, and Ocella lines of birth control pills when they agreed to settle 1,200 claims for $56.9 million. Their birth control pills allegedly caused blood clots, strokes, and heart attacks in women.
Previously, Bayer had paid around $2 billion to settle similar claims for their birth control pills.
$650 Million Pradaxa Settlement (2014)
Boehringer Ingelheim, the manufacturer of the blood thinner Pradaxa, was linked to severe and fatal cases of excessive bleeding, similar to Xarelto. One thousand patients died of complications caused by the drug before an antidote was available in October 2015.
Xarelto presents an even higher risk of excessive bleeding than Pradaxa.
In 2012, 4,000 claims were consolidated in a multidistrict litigation, accusing the company of failure to warn and wrongful death. Boehringer Ingelheim tried to resist litigation and allegedly thwarted the discovery process when 50,000 documents were lost, resulting in a $1 million fine. Their efforts were fruitless in the end; in 2014, Boehringer Ingelheim agreed to pay $650 million to settle all 4,000 claims. On average, each claimant received around $162,500.
According to a study published by JAMA Internal Medicine, Xarelto presents an even higher risk of excessive bleeding than Pradaxa. Because of this, Xarelto lawsuits are likely to result in similarly large settlements.
ClassAction.com Will Help You Fight Back
Similar pharmaceutical settlements suggest that Xarelto is likely to pay millions of dollars in compensation to affected patients and loved ones.
If you or a family member suffered uncontrollable bleeding as a result of taking Xarelto, it isn’t too late to file a lawsuit. Contact us today for a free, no-obligation case review. Our team of more than 300 attorneys has recovered $2 billion for clients.